These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Diagnosis and management of cholestatic liver disease. Heathcote EJ Clin Gastroenterol Hepatol; 2007 Jul; 5(7):776-82. PubMed ID: 17628332 [TBL] [Abstract][Full Text] [Related]
25. Pulmonary prognosis in cystic fibrosis patients with liver disease. Slieker MG; van der Doef HP; Deckers-Kocken JM; van der Ent CK; Houwen RH J Pediatr; 2006 Jul; 149(1):144; author reply 144-5. PubMed ID: 16860146 [No Abstract] [Full Text] [Related]
26. Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation. Demeilliers C; Jacquemin E; Barbu V; Mergey M; Paye F; Fouassier L; Chignard N; Housset C; Lomri NE Hepatology; 2006 May; 43(5):1125-34. PubMed ID: 16628629 [TBL] [Abstract][Full Text] [Related]
27. Screening for liver disease in cystic fibrosis: analysis of clinical and genetic risk factors for its development. Fustik S; Trajkovska M; Jakovska T; Spirevska L; Josifovska T; Koceva S Turk J Pediatr; 2008; 50(6):526-32. PubMed ID: 19227414 [TBL] [Abstract][Full Text] [Related]
29. Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests. Abraham SC; Poterucha JJ; Rosen CB; Demetris AJ; Krasinskas AM Am J Surg Pathol; 2008 Jul; 32(7):965-73. PubMed ID: 18460980 [TBL] [Abstract][Full Text] [Related]
30. [Digestive alterations in cystic fibrosis. Retrospective study of a series of 46 adult patients]. Pérez-Aguilar F; Ferrer-Calvete J; Nicolás D; Berenguer J; Ponce J Gastroenterol Hepatol; 1999 Feb; 22(2):72-8. PubMed ID: 10193090 [TBL] [Abstract][Full Text] [Related]
31. [Cystic fibrosis in adults]. Polu JM; Lesur O; Delorme N Rev Prat; 1990 Jun; 40(17):1581-6. PubMed ID: 2363014 [TBL] [Abstract][Full Text] [Related]
32. [Laparoscopic cholecystectomy--accessory bile ducts]. Balija M; Huis M; Szerda F; Bubnjar J; Stulhofer M Acta Med Croatica; 2003; 57(2):105-9. PubMed ID: 12879689 [TBL] [Abstract][Full Text] [Related]
33. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Paumgartner G; Beuers U Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643 [TBL] [Abstract][Full Text] [Related]
34. Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis. Kinnman N; Lindblad A; Housset C; Buentke E; Scheynius A; Strandvik B; Hultcrantz R Hepatology; 2000 Aug; 32(2):334-40. PubMed ID: 10915740 [TBL] [Abstract][Full Text] [Related]
35. Intensive care management of the patient with cystic fibrosis. Kremer TM; Zwerdling RG; Michelson PH; O'Sullivan P J Intensive Care Med; 2008; 23(3):159-77. PubMed ID: 18443012 [TBL] [Abstract][Full Text] [Related]
36. Successful lung transplantation in spite of cystic fibrosis-associated liver disease: a case series. Klima LD; Kowdley KV; Lewis SL; Wood DE; Aitken ML J Heart Lung Transplant; 1997 Sep; 16(9):934-8. PubMed ID: 9322144 [TBL] [Abstract][Full Text] [Related]
37. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. Debray D; Kelly D; Houwen R; Strandvik B; Colombo C J Cyst Fibros; 2011 Jun; 10 Suppl 2():S29-36. PubMed ID: 21658639 [TBL] [Abstract][Full Text] [Related]
38. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Colombo C; Castellani MR; Balistreri WF; Seregni E; Assaisso ML; Giunta A Hepatology; 1992 Apr; 15(4):677-84. PubMed ID: 1551646 [TBL] [Abstract][Full Text] [Related]